Peptide Glossary

Key terms and definitions used in peptide research and science. Use this glossary to better understand the technical language in our content.

101 terms

A

Amino Acid: The building blocks of peptides and proteins. There are 20 standard amino acids used in biological systems.
Anabolic: Relating to the synthesis of complex molecules from simpler ones, typically involving tissue building.
Angiogenesis: The formation of new blood vessels from existing vessels. Important for tissue repair and healing.
Agonist: A substance that binds to a receptor and activates it, producing a biological response. For example, semaglutide is a GLP-1 receptor agonist.
Antagonist: A substance that binds to a receptor and blocks its activation, preventing a biological response.
Autophagy: A cellular self-cleaning process where damaged or dysfunctional components are broken down and recycled. Some peptides may modulate autophagic pathways.
Allosteric Modulation: A mechanism where a molecule binds to a site other than the active site on a receptor, altering the receptor's response to its primary ligand.
Affinity: The strength of binding between a ligand (such as a peptide) and its receptor. Higher affinity means the peptide binds more tightly to its target.

B

Bioavailability: The proportion of a substance that enters circulation when introduced into the body and is able to have an active effect.
Bacteriostatic Water: Sterile water containing 0.9% benzyl alcohol as a preservative, used for reconstituting lyophilised peptides for research purposes.
Bioequivalence: The property of pharmaceutical products that have the same rate and extent of absorption of the active ingredient when administered at the same dose.
Blood-Brain Barrier (BBB): A selective barrier formed by endothelial cells lining brain capillaries that restricts the passage of most substances from the bloodstream into brain tissue. A major challenge for CNS-targeting peptides.
Bioaccumulation: The gradual accumulation of a substance in the body over time with repeated dosing. Most peptides do not bioaccumulate due to their short half-lives.

C

Catabolic: Relating to the breakdown of complex molecules into simpler ones, typically releasing energy.
Cytokine: Small proteins important in cell signalling, particularly in immune and inflammatory responses.
Certificate of Analysis (COA): A document from a third-party laboratory confirming the purity, identity, and quality of a peptide or chemical compound.
Collagen: The most abundant structural protein in the body, found in skin, tendons, ligaments, and bone. Multiple types exist (I, II, III), each with different functions.
Clinical Trial: A research study conducted in human participants to evaluate the safety and efficacy of a treatment. Phases range from Phase I (safety) through Phase III (efficacy) to Phase IV (post-marketing).
Chaperone Protein: A protein that assists in the folding, assembly, and stabilisation of other proteins and peptides, ensuring they achieve their correct three-dimensional structure.
Clearance Rate: The rate at which a substance is removed from the body, typically measured as volume of blood cleared per unit time. Determines how quickly a peptide is eliminated.
Circadian Rhythm: The body's internal 24-hour clock that regulates hormone secretion, metabolism, and sleep. Some peptides are more effective when dosed at specific times of day.
Cycling: Alternating periods of peptide use (on-cycle) with breaks (off-cycle) to prevent tolerance, maintain receptor sensitivity, and allow natural hormone axis recovery.

D

DPP-4 (Dipeptidyl Peptidase-4): An enzyme that rapidly degrades endogenous GLP-1 and GIP. DPP-4-resistant analogues such as semaglutide have extended half-lives for therapeutic use.
Desensitisation: A decrease in receptor responsiveness following prolonged or repeated exposure to an agonist. Relevant to peptide cycling protocols and tolerance development.
Downregulation: The decrease in the number of receptors or the sensitivity of receptors to a ligand, often in response to prolonged stimulation.
Dose-Response Curve: A graphical representation of the relationship between the dose of a substance and the magnitude of its biological effect. Used to determine optimal dosing ranges.

E

Endocrine: Relating to glands that secrete hormones directly into the bloodstream.
Endogenous: Originating from within the organism. Endogenous peptides are naturally produced by the body.
Exogenous: Originating from outside the organism. Exogenous peptides are introduced from external sources.
Enteric Coating: A polymer coating on a tablet or capsule that prevents dissolution in the stomach, allowing release in the intestine. Used in some oral peptide formulations.
EC50: The concentration of a substance that produces 50% of its maximal possible effect. A key measure of a peptide's potency at its target receptor.
Efficacy: The maximum biological effect a substance can produce. Distinct from potency, which measures the dose needed to achieve an effect.
Enzymatic Degradation: The breakdown of peptides by proteolytic enzymes in the blood, gut, or tissues. A major barrier to oral peptide bioavailability.
Endotoxin: Toxic components of bacterial cell walls that can contaminate poorly manufactured peptides. Endotoxin testing (LAL test) is a critical quality control measure.

F

Fibroblast: A cell type in connective tissue that produces collagen and other components of the extracellular matrix. A key target of tissue-repair and cosmetic peptides.
First-Pass Effect: The phenomenon where a drug is metabolised in the liver before reaching systemic circulation, significantly reducing its bioavailability. A major barrier to oral peptide delivery.
Freeze-Thaw Cycle: The process of freezing and then thawing a reconstituted peptide solution. Repeated freeze-thaw cycles can denature peptides and reduce potency.

G

Growth Factor: Naturally occurring substances capable of stimulating cell growth, proliferation, and differentiation.
GLP-1 (Glucagon-Like Peptide-1): An incretin hormone that stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety. The basis for drugs such as semaglutide and liraglutide.
GIP (Glucose-Dependent Insulinotropic Polypeptide): An incretin hormone targeted by dual agonists like tirzepatide. Works alongside GLP-1 to regulate insulin secretion and energy metabolism.
Ghrelin: A peptide hormone produced primarily in the stomach that stimulates appetite and growth hormone release. The natural ligand for the GHS-R1a receptor.
Glycosylation: The attachment of sugar molecules to a peptide or protein, which can affect its stability, folding, and biological activity.
GMP (Good Manufacturing Practice): Quality standards for the manufacture of pharmaceutical products. GMP-certified peptides are produced under strict controls for purity and consistency.

H

Half-Life: The time required for the concentration of a substance to reduce to half its initial value.
Homeostasis: The tendency of biological systems to maintain stable internal conditions.
HPLC (High-Performance Liquid Chromatography): An analytical technique used to separate, identify, and quantify components in a mixture. The standard method for assessing peptide purity.

I

In Vitro: Studies conducted outside of living organisms, typically in laboratory conditions (e.g., in test tubes or cell cultures).
In Vivo: Studies conducted within living organisms.
Incretin: A gut hormone released after eating that stimulates insulin secretion in a glucose-dependent manner. GLP-1 and GIP are the two primary incretins.
Intramuscular (IM): Administration by injection into a muscle. Some peptides are administered via intramuscular injection for research purposes, offering faster absorption than subcutaneous routes.
Intranasal: Administration through the nasal mucosa. Used for peptides such as semax, selank, and oxytocin, which can cross the blood-brain barrier via this route.
IC50: The concentration of an inhibitor required to reduce a biological process by 50%. Used to measure the potency of antagonists or enzyme inhibitors.
Isomer: Molecules with the same chemical formula but different structural arrangements. Peptides use L-form amino acids naturally; D-form isomers resist enzymatic degradation.

L

Ligand: A molecule that binds to a receptor to produce a biological response.
Lyophilization: Freeze-drying process used to preserve peptides by removing water content.
Lyophilised: Freeze-dried. Peptides are typically supplied as lyophilised powders for improved stability during storage and shipping.
Lipodystrophy: Abnormal distribution of fat tissue, which can occur at injection sites due to repeated subcutaneous injections. Managed through proper site rotation.

M

Mechanism of Action: The specific biochemical interaction through which a substance produces its effect.
MHRA: Medicines and Healthcare products Regulatory Agency. The UK body responsible for regulating medicines, medical devices, and blood components for supply.
Mass Spectrometry: An analytical technique that measures the mass-to-charge ratio of ions, used to confirm the molecular identity of peptides.
Myokine: A cytokine or peptide produced and released by muscle fibres during contraction. Exercise-induced myokines mediate some of the systemic benefits of physical activity.
Myostatin: A protein (GDF-8) that inhibits muscle growth. Myostatin inhibitors like follistatin and ACE-031 are researched for promoting muscle hypertrophy.

N

Neuropeptide: Peptides found in neural tissue that act as neurotransmitters or neuromodulators.
NICE: National Institute for Health and Care Excellence. Issues clinical guidelines and technology appraisals that determine NHS treatment availability in England and Wales.

O

Oral Bioavailability: The fraction of an orally administered dose that reaches systemic circulation in its active form. Typically very low for peptides due to enzymatic degradation and poor absorption.
Off-Target Effects: Biological effects caused by a peptide binding to receptors or pathways other than its intended target. A common source of side effects.

P

Peptide Bond: The covalent chemical bond linking amino acids together in a peptide chain.
Pharmacodynamics: The study of how drugs affect the body, including mechanisms of action and effects.
Pharmacokinetics: The study of how the body affects drugs, including absorption, distribution, metabolism, and excretion.
Preclinical: Research stage before human clinical trials, typically involving laboratory and animal studies.
Prescription Only Medicine (POM): A medicine that can only be legally obtained with a valid prescription from an authorised prescriber in the UK.
Peptide Sequence: The specific linear order of amino acids in a peptide chain, written from the N-terminus to the C-terminus. Determines the peptide's three-dimensional structure and biological function.
PEGylation: The attachment of polyethylene glycol (PEG) chains to a peptide or protein to increase its half-life by reducing renal clearance and proteolytic degradation.
Pleiotropic: Having multiple effects on different biological pathways or systems. BPC-157 is often described as pleiotropic due to its wide range of researched activities.
Post-Translational Modification: Chemical modifications made to a peptide or protein after it has been synthesised, including phosphorylation, acetylation, and glycosylation. These modifications can alter function and stability.
Phase I/II/III Trial: The three main phases of clinical drug development. Phase I tests safety in small groups, Phase II tests efficacy and dosing, Phase III confirms efficacy in large populations.
Potency: The amount of a substance required to produce a given effect. A more potent peptide achieves the same result at a lower dose.
Pituitary Downregulation: Reduced sensitivity or output from the pituitary gland after prolonged stimulation by exogenous peptides, particularly growth hormone secretagogues.

R

Receptor: A protein on the cell surface or inside cells that binds to specific molecules (ligands) to trigger a response.
Reconstitution: The process of adding liquid (typically bacteriostatic water) to lyophilized peptides to make them injectable.
RCT (Randomised Controlled Trial): A study design where participants are randomly assigned to treatment or control groups, considered the gold standard for evaluating therapeutic efficacy.

S

Secretagogue: A substance that promotes the secretion of another substance, such as growth hormone secretagogues.
Signal Transduction: The process by which a cell converts one kind of signal into another.
Subcutaneous: Administration under the skin. Common route for peptide injections.
Synthesis: The production of peptides through chemical or biological processes.
Somatotroph: A cell in the anterior pituitary gland that produces and secretes growth hormone. Targeted by growth hormone secretagogue peptides.
Somatopause: The age-related decline in growth hormone secretion, typically beginning in the third or fourth decade of life.
SNAC (Sodium N-[8-(2-Hydroxybenzoyl) Amino] Caprylate): An absorption enhancer used in oral semaglutide (Rybelsus) to facilitate peptide absorption across the gastric mucosa.
Selectivity: The ability of a peptide to preferentially bind to and activate one receptor type over others. Higher selectivity generally means fewer off-target side effects.
Steady State: The point during repeated dosing at which the rate of drug administration equals the rate of elimination, resulting in stable plasma concentrations.
Sarcopenia: Age-related progressive loss of skeletal muscle mass and strength. Growth hormone secretagogues and other peptides are researched as potential interventions.

T

Therapeutic Index: The ratio between the toxic dose and the therapeutic dose of a substance.
Tachyphylaxis: A rapid decrease in response to a drug following repeated administration. Relevant to peptide cycling discussions and receptor desensitisation.
Telomere: The protective cap at the end of chromosomes that shortens with each cell division and with age. Studied in relation to the peptide Epitalon.
Telomerase: An enzyme that adds DNA sequence repeats to telomere ends, potentially slowing cellular ageing. Epitalon is studied for its effects on telomerase activity.
Transdermal: Administration through the skin, typically via patches, creams, or serums. Some peptides such as GHK-Cu can be delivered transdermally for topical effects.
Tolerance: A reduced response to a substance after repeated use, requiring higher doses to achieve the same effect. Distinct from tachyphylaxis, which occurs more rapidly.

U

Upregulation: The increase in the number of receptors or the sensitivity of receptors to a ligand.

W

WADA: World Anti-Doping Agency. Maintains the Prohibited List of substances banned in competitive sport, including many peptides and growth hormone secretagogues.
Washout Period: A period between treatment cycles during which no drug is administered, allowing the substance to be fully eliminated from the body. Relevant to peptide cycling protocols.

X

Xenobiotic: A chemical substance not naturally produced by or expected to be present within the body. Exogenous peptides administered for research purposes are xenobiotics.